Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment
Cocrystal Pharma dosed the last subject in its Phase 1b human challenge study (NCT07198139) evaluating CDI-988 as both a preventive and treatment for norovirus, with no serious adverse events reported to date. The randomized, double-blind, placebo-controlled trial is being run at Emory University School of Medicine, dosing healthy subjects ages 18-49 infected with the GII.2 Snow Mountain Virus strain at the 1200 mg dose established as safe in an earlier Phase 1 study in Australia.
Key figures
- Drug Name
- CDI-988
- Phase Of Trial
- Phase 1b
- Trial site
- Emory University School of Medicine
- Challenge strain
- norovirus GII.2 (Snow Mountain Virus)
- Dose administered
- 1200 mg
- Study registration
- NCT07198139
- Preliminary data timing
- late 2026 or early 2027
- Highest phase1 dose tested
- 1200 mg
- Norovirus us annual burden
- $10.6 billion
- Norovirus global cases annually
- 685 million
- Norovirus global economic impact
- $60 billion
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.